Tags

Type your tag names separated by a space and hit enter

New antiepileptic drugs in pediatric epilepsy.
Brain Dev. 2008 Oct; 30(9):549-55.BD

Abstract

New antiepileptic drugs (AEDs), introduced since 1993, provide more diverse options in the treatment of epilepsy. Despite the equivalent efficacy and better tolerability of these drugs, more than 25% of patients remain refractory to treatment. Moreover, the issues for pediatric patients are different from those for adults, and have not been addressed in the development and application of the new AEDs. Recently published evidence-based treatment guidelines have helped physicians to choose the most reasonable AED, although they cannot fully endorse new AEDs because of the lack of well-designed, randomized controlled trials. We review the mechanisms of action, pharmacokinetic properties, adverse reactions, efficacy, and tolerability of eight new AEDs (felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, topiramate, vigabatrin, and zonisamide), focusing on currently available treatment guidelines and expert opinions regarding pediatric epilepsy.

Authors+Show Affiliations

Department of Pediatrics, Seoul National University Childern's Hospital, 28 Yongon-dong, Jongno-gu, Seoul 110-744, South Korea.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18328657

Citation

Hwang, Hee, and Ki Joong Kim. "New Antiepileptic Drugs in Pediatric Epilepsy." Brain & Development, vol. 30, no. 9, 2008, pp. 549-55.
Hwang H, Kim KJ. New antiepileptic drugs in pediatric epilepsy. Brain Dev. 2008;30(9):549-55.
Hwang, H., & Kim, K. J. (2008). New antiepileptic drugs in pediatric epilepsy. Brain & Development, 30(9), 549-55. https://doi.org/10.1016/j.braindev.2008.01.007
Hwang H, Kim KJ. New Antiepileptic Drugs in Pediatric Epilepsy. Brain Dev. 2008;30(9):549-55. PubMed PMID: 18328657.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - New antiepileptic drugs in pediatric epilepsy. AU - Hwang,Hee, AU - Kim,Ki Joong, Y1 - 2008/03/06/ PY - 2007/09/17/received PY - 2008/01/21/revised PY - 2008/01/21/accepted PY - 2008/3/11/pubmed PY - 2008/10/16/medline PY - 2008/3/11/entrez SP - 549 EP - 55 JF - Brain & development JO - Brain Dev VL - 30 IS - 9 N2 - New antiepileptic drugs (AEDs), introduced since 1993, provide more diverse options in the treatment of epilepsy. Despite the equivalent efficacy and better tolerability of these drugs, more than 25% of patients remain refractory to treatment. Moreover, the issues for pediatric patients are different from those for adults, and have not been addressed in the development and application of the new AEDs. Recently published evidence-based treatment guidelines have helped physicians to choose the most reasonable AED, although they cannot fully endorse new AEDs because of the lack of well-designed, randomized controlled trials. We review the mechanisms of action, pharmacokinetic properties, adverse reactions, efficacy, and tolerability of eight new AEDs (felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, topiramate, vigabatrin, and zonisamide), focusing on currently available treatment guidelines and expert opinions regarding pediatric epilepsy. SN - 0387-7604 UR - https://www.unboundmedicine.com/medline/citation/18328657/New_antiepileptic_drugs_in_pediatric_epilepsy_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0387-7604(08)00026-0 DB - PRIME DP - Unbound Medicine ER -